0000000000004396
AUTHOR
Ida Pucci
showing 94 related works from this author
Multi-omics analysis of epithelial-to mesenchymal transition mediators in breast cancer
2022
Analysis of Trastuzumab effects in breast cancer cells in vitro
2011
Effects of endothelial cells on breast cancer cells in a co-culture system.
2007
Decorin transfection induces proteomic modulation and cytoskeletal rioganization in breast cancer cells (8701-BC)
2003
Occurrence of S100A7 in a large sample-set of breast cancer tissues
2010
Modulation of neoplastic phenotype by Extracellular Matrix components.
2006
Proteomic approach to characterize homozygous Citrus clementina Hort. ex Tan. Genotypes
2011
Clinicopathological correlations of MMP-2 and MMP-9 in breast cancer
2009
Proteomic modulation of breast cancer cells (8701-BC) cocultured with normal human fibroblasts.
2004
Differential proteomics of thyroid carcinoma cell lines
2011
Proteomic modulation in breast cancer cells
2003
Levels of circulating gelatinases and proteomic correlations in breast cancer patients.
2008
Anti-oncogenic role of decorin: identification of new markers.
2009
Fibroblast’s role in breast cancer: a proteomic approach
2008
Fibroblasts are the major mesenchymal cell types committed to the matrix formation and renewal. Moreover they are the main source of paracrine factors that influence the growth of epithelial cells of neighbouring tissues. For these properties they may be involved in tumourigenesis, either by remodelling the tumor-associated extracellular matrix (ECM), and by the production of paracrine factors that influence the growth of carcinoma cells. Studies on fibroblasts associated to carcinomas have documented their phenotypic modifications, including abnormal migratory behaviour in vitro and growth factors altered expression(Schor & Schor, 2001). In addition, fibroblasts often recruit inflammat…
Proteomic Detection of Breast-Cancer Subpopulations.
2007
Decorin transfection in breast cancer cells (8701-BC) induces proteomic modulation, cytoskeleton reorganization and inhibits matrix proteases
2004
Comparative Proteomic and immunohistochemistry analyses to study alphaenolase/MBP-1 isoforms expression in breast cancer
2007
Proteomic analysis of extracellular vesicles shed in vitro by MDA MB 231 breast carcinoma cells
2010
Cross talk between tumor cells and connective tissue plays a key role in tumor progression. The communication is due to the release of signalling molecules from both tumor cells and surrounding stromal cells. Several secreted proteins lack the N-terminal signal peptides and, therefore, they are secreted by alternative unconventional processes such as secretion mechanism mediated by vesicle shedding in the extracellular matrix. Actually, a certain number of proteins, playing roles in some aspects of tumor progression, have been found in shed vesicles. For example, EMMPRIN, carried out in vesicles shed by tumor cells, stimulates matrix metalloproteinase (MMP) production in stromal fibroblasts…
Herceptin Resistance and Malignant Potential of Cancer Cells.
2009
The fibroblasts: co-actors in cancer.
2008
PROTEOMIC EFFECTS INDUCED BY MICROENVIRONMENT COMPONENTS ON 8701-BC BREAST CANCER CELLS: AN UPDATED REPORT
2013
Proteomic analysis of Herceptin-resistance breast cancer cells
2009
Differential proteomic and phenotypic behavior of papillary and anaplastic thyroid carcinoma cell lines: an updated study
2012
Breast cancer proteomics: from research to clinical applications.
2008
The exponentially increasing volume of information extracted from genomic and proteomic applications on cancer, while providing new insights into molecular composition of cancer cells and tissues, imposes new challenges on data rationalization as a tool for clinically relevant biomarker discovery. Breast cancer represents the most frequent and potentially aggressive type of cancer and, moreover, it is one of the most enigmatic and poorly predictable in its evolution, likely because it includes several different forms that behave differently among patients. Current clinical parameters for breast cancer diagnosis and cure are: tumour size, axillary lymph node status, histological grading and …
Ectopic decorin induces proteomic and cytoskeleton modulation of breast cancer cells
2005
Fibroblast-derived factors modulate breast cancer cell proteomics.
2005
S100S PROTEIN EXPRESSION IN A LARGE SAMPLE-SET OF BREAST CANCER TISSUES
2010
S100 proteins are low molecular weight proteins ranging in size from 9 to 13 kDa. They form homo- and heterodimers and even oligomers and are expressed in tissue and cell-specific manner [1]. It is well documented, infact, that S100 proteins have a broad range of intracellular and extracellular functions. Intracellular functions include regulation of protein phosphorylation, enzyme activity, calcium homeostasis, regulation of cytoskeletal components and regulation of transcriptional factors, so they are involved in several biological processes including cell cycle regulation, cell growth, cell differentiation, and motility [2]. Extracellularly they act in a cytokine like manner through the …
Zymographic detection of MMP-2 and MMP-9 in breast cancer sera patients during chemotherapy.
2007
Cross-talk between fibroblast and breast cancer cells: a proteomic study
2003
MMP-2, MMP-9 and MMP-14 in breast cancer: clinicopathological correlations.
2009
Analisi di cluster proteomici per l'identificazione di sottopopolazioni di pazienti con carcinoma mammario
2013
Evaluation of cellular response of breast cancer cells grown on distinctive collagen substrates
2008
Extraction of Proteins From Leaves of Homozygous and Heterozygous Citrus for Two-Dimensional Electrophoresis Analysis.
2009
LARGE-SCALE COMPARATIVE PROTEOMICS OF BREAST CANCER SURGICAL TISSUES
2009
Studio dell'interattoma di PAR-6 in cellule di carcinoma mammario 8701-BC
2013
Comparative proteomics of breast cancer surgical tissues
2009
Cytoskeleton modulation in breast cancer cells induced by stromal microenvironment.
2004
Zymographic detection of matrix proteases in breast cancer biopsies by mono- and two-dimensional electrophoresis
2004
Genomic and proteomic profiling of decorin transfected breast cancer cells.
2006
Correlation between MMPS and proteomic profiles of breast cancer tissues
2009
Gene ontology-based annotation and comparative analysis of proteins extracted from proteomics of 100 breast cancer patients.
2009
Background: Current clinical parameters for breast cancer diagnosis and therapy are: tumour size, axillary lymph node status, histological grading and presence or absence of metastases. Prognostic/predictive properties, such as oestrogen and progesterone receptor status, and human epidermal growth factor receptor (HER-2/neu) status are currently used for therapeutic decision. Conversely, it is now emerging that the number of genetic mutations and epigenetic deregulations in cancer is far more higher than previously thought. Therefore, proteomic screening for differential protein expression in subsets of tumor samples is an essential tool for generating data bases and biomarker discovery. Th…
A proteomic cluster for osteotropic breast cancer cells
2014
Effects of Hypoxia on 8701-BC cancer cells.
2007
Proteomic profiling of B-cell chronic lymphocytic leukemia. A pilot study.
2004
PROTEOMIC SIGNATURE OF BREAST CANCER TISSUES FOR PATIENTS STRATIFICATION
2012
Proteomic modulation induced in fibroblasts by breast cancer cells (8701‐BC)paracrine factors.
2009
Proteomic and genomic modulations of breast cancer cells co-cultured with endothelial cells.
2007
La post-genomica in Oncologia: prospettive e problematiche. Analisi proteomica
2005
Analisi comparativa tra linee cellulari di carcinoma tiroideo papillare ed anaplastico
2013
Modulazione del proteoma indotta in cellule di carcinoma mammario da decorina ectopica
2004
Large-scale proteomic identification of S100 proteins in breast cancer tissues
2010
Abstract Background Attempts to reduce morbidity and mortality in breast cancer is based on efforts to identify novel biomarkers to support prognosis and therapeutic choices. The present study has focussed on S100 proteins as a potentially promising group of markers in cancer development and progression. One reason of interest in this family of proteins is because the majority of the S100 genes are clustered on a region of human chromosome 1q21 that is prone to genomic rearrangements. Moreover, there is increasing evidence that S100 proteins are often up-regulated in many cancers, including breast, and this is frequently associated with tumour progression. Methods Samples of breast cancer t…
Effetti indotti da fattori diffusibili fibroblastici sull'espressione proteica di cellule di carcinoma mammario.
2004
Cross-talk between breast cancer cells and fibroblasts in coculture system.
2005
CIRCULATING AND TISSUE FORMS OF MMP2 AND MMP9 IN BREAST CANCER PROGRESSION
2010
Tumor progression and metastasis represent the leading causes of cancer related death. One of the major features that may contribute to neoplastic cell dissemination is the progressive and local degradation of the extracellular matrix (ECM) surrounding the primary tumour. Degradation of the ECM requires the coordinated action of a number of enzymes produced locally by neoplastic cells and/or stromal cells. Five categories of proteinases have been implicated in the invasive process: serine, cysteine, aspartic, threonine proteinases and matrix metalloproteinases (MMPs), also known as matrixins, which play a key role as terminal effectors of the proteolytic cascade. At present 23 members of th…
Comparative detection of matrix metalloproteinase-2 and -9, interleukin-6 and c-reactive protein in breast cancer serum of patients during neoadjuvan…
2007
Fibroblast’s influence on breast cancer cells.
2006
Effects of fibroblast diffusible factors on proteomic modulation of breast cancer cells.
2005
Ectopic decorin induces proteomic and phenotypic modulation of breast cancer cells.
2005
The cytoskeletal network in fibroblasts cultured from PXE patients
2004
Proteomics and proteomic modulations of breast cancer cells
2004
DIFFERENTIAL PROTEOMIC ANALYSIS OF THYROID CARCINOMA CELL LlNES
2011
Herceptin-resistance in breast cancer cells: a proteomic study.
2009
HER-2 is a cell membrane protein that belongs to the ErbB family of receptor tyrosine kinases (HER-1, HER-2, HER-3, HER-4). The over-expression of HER-2, which results in the 25-30% of breast cancer patients, is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness and makes HER-2 an excellent therapeutic target. In the last years new therapeutic strategies have been improved in order to better deal tumor diseases an to minimize collateral effects due to classic chemotherapy in patients. In this way, a new approach was the somministration of humanized antibodies directed against tumor-associated molecular targets. Among these ones Herceptin, an anti-neo…
Proteomic detection of S100 proteins in breastcancer tissues
2010
Urinary Proteomic Profile Of A Multiple Myeloma Affected Patient
2012
Involvement of gelatinases in breast cancer: correlation with clinical parameters and 2D-IPG applications.
2004
Multiple effects induced by herceptin® on 8701-BC breast cancer cells
2008
Herceptin, an anti-neoplastic humanized monoclonal antibody (Herceptin®, Roche, CH), has been shown to be active against breast cancer cells over-expressing HER-2 receptor. HER-2 is a cell membrane protein that belongs to the epidermal growth factor receptors family and that results over-expressed in the 25-30% of breast cancer patients. The over-expression of HER-2 is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness. On these bases, we aimed to analyze the effects caused by Herceptin treatment on 8701-BC breast cancer cells (Minafra et al., 1989). Firstly we evaluated the effects of Herceptin on the growth rate of 8701-BC cells. To this purpose, p…
New insight on genomic and proteomic profiling of decorin-transfected breast cancer cells.
2007
LARGE-SCALE SCREENING OF MATRIX METALLOPROTEINASES IN BREAST CANCER PATIENTS AND CLINICAL-MOLECULAR CORRELATIONS
2009
Cytoskeleton and Proteomic Changes Induced by Fibroblasts on Breast Cancer Cells
2007
Herceptin-resistance in breast cancer cells: a proteomic approach
2009
Proteomic profile of hypoxic breast cancer cells
2007
Large-scale comparative proteomics of breast surgical tissues
2009
IDENTIFICATION OF TYPE V COLLAGEN-BINDING PROTEINS IN 8701-BC BREAST CANCER CELLS
2012
Proteomica comparata di un frammento chirurgico di carcinoma del colon e della metastasi epatica associata
2013
Circulating levels of Matrix Metalloproteinases (MMP-2 and MMP-9), CRP and IL-6 during therapeutic treatment of patients with breast cancer
2008
S-100 calcium binding proteins as potential markers for breast cancer metastasis.
2009
The S-100 family of calcium-binding proteins includes about 20 members of low molecular weight characterized by two consecutive EF hands domains. They make interactions with cellular target proteins in a calcium-dependent manner; therefore they are thought to regulate a variety of physiological functions, such as cell proliferation, signal transduction, cell adhesion, motility as well as cancer metastasis.
Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gr…
2005
ackground: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). This combination shows a relevant toxicity and new chemotherapy associations with a more favourable toxicity profile are awaited. Carboplatin (CB) is a platinum derivative with less toxicity than CDDP. Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC. Materials and Methods: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxic…
Permissive and restrictive influences from breast cancer stroma
2010
The turn-over of extracellular matrix is a physiological process, that in normal conditions and in wound healing respond to spatial and temporal regulatory mechanisms, involving several cell-matrix interaction pathways. Profound changes occur both at cellular and extracellular level, during the progression of various forms of invasive carcinomas. Collagen alterations and cellular effects. The ultrastructural and biochemical analyses of the collagenous stroma of invasive ductal breast carcinoma have demonstrated the occurrence of extensive fragmentation of pre-existing collagen fibrils and new deposition of thinner fibrils formed mostly by 1(I)3 homotrimer collagen of type I [1-3], which app…